These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 18248994)

  • 1. Fused bicyclic pyrrolizinones as new scaffolds for human NK1 antagonists.
    Morriello GJ; Devita RJ; Mills SG; Young JR; Lin P; Doss G; Chicchi GG; Demartino J; Kurtz MM; Tsao KL; Carlson E; Townson K; Wheeldon A; Boyce S; Collinson N; Rupniak N; Moore S
    Bioorg Med Chem; 2008 Mar; 16(5):2156-70. PubMed ID: 18248994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substituted fused bicyclic pyrrolizinones as potent, orally bioavailable hNK1 antagonists.
    Morriello GJ; Mills SG; Johnson T; Reibarkh M; Chicchi G; DeMartino J; Kurtz M; Davies P; Tsao KL; Zheng S; Tong X; Carlson E; Townson K; Tattersall FD; Wheeldon A; Boyce S; Collinson N; Rupniak N; Moore S; DeVita RJ
    Bioorg Med Chem Lett; 2010 Mar; 20(6):2007-12. PubMed ID: 20153964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fused tricyclic pyrrolizinones that exhibit pseudo-irreversible blockade of the NK1 receptor.
    Morriello GJ; Chicchi G; Johnson T; Mills SG; Demartino J; Kurtz M; Tsao KL; Zheng S; Tong X; Carlson E; Townson K; Wheeldon A; Boyce S; Collinson N; Rupniak N; Devita RJ
    Bioorg Med Chem Lett; 2010 Oct; 20(19):5925-32. PubMed ID: 20729082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.
    Di Fabio R; Alvaro G; Braggio S; Carletti R; Gerrard PA; Griffante C; Marchioro C; Pozzan A; Melotto S; Poffe A; Piccoli L; Ratti E; Tranquillini E; Trower M; Spada S; Corsi M
    Bioorg Med Chem; 2013 Nov; 21(21):6264-73. PubMed ID: 24075145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationships of 8-azabicyclo[3.2.1]octane benzylamine NK1 antagonists.
    Thomson CG; Carlson E; Chicchi GG; Kulagowski JJ; Kurtz MM; Swain CJ; Tsao KL; Wheeldon A
    Bioorg Med Chem Lett; 2006 Feb; 16(4):811-4. PubMed ID: 16307878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tetrahydroindolizinone NK1 antagonists.
    Bao J; Lu H; Morriello GJ; Carlson EJ; Wheeldon A; Chicchi GG; Kurtz MM; Tsao KL; Zheng S; Tong X; Mills SG; DeVita RJ
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2354-8. PubMed ID: 20188553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of the C12-C19 fragment of (+)-peloruside A through a diastereomer-discriminating RCM reaction.
    Roulland E; Ermolenko MS
    Org Lett; 2005 May; 7(11):2225-8. PubMed ID: 15901175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a series of 3-(benzyloxy)-1-azabicyclo[2.2.2]octane human NK1 antagonists.
    Swain CJ; Seward EM; Cascieri MA; Fong TM; Herbert R; MacIntyre DE; Merchant KJ; Owen SN; Owens AP; Sabin V
    J Med Chem; 1995 Nov; 38(24):4793-805. PubMed ID: 7490729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-component domino process for the pyrrolizine skeleton via [3 + 2]-cycloaddition-enamine cyclization triggered by a gold catalyst.
    Sugimoto K; Yamamoto N; Tominaga D; Matsuya Y
    Org Lett; 2015 Mar; 17(5):1320-3. PubMed ID: 25700009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formation of bicyclic pyrroles from the catalytic coupling reaction of 2,5-disubstituted pyrroles with terminal alkynes, involving the activation of multiple C-H bonds.
    Yi CS; Zhang J
    Chem Commun (Camb); 2008 May; (20):2349-51. PubMed ID: 18473066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel potent 5-HT(1F) receptor agonists: structure-activity studies of a series of substituted N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides.
    Filla SA; Mathes BM; Johnson KW; Phebus LA; Cohen ML; Nelson DL; Zgombick JM; Erickson JA; Schenck KW; Wainscott DB; Branchek TA; Schaus JM
    J Med Chem; 2003 Jul; 46(14):3060-71. PubMed ID: 12825944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mild and efficient DBU-catalyzed amidation of cyanoacetates.
    Price KE; Larrivée-Aboussafy C; Lillie BM; McLaughlin RW; Mustakis J; Hettenbach KW; Hawkins JM; Vaidyanathan R
    Org Lett; 2009 May; 11(9):2003-6. PubMed ID: 19341310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition.
    Fancelli D; Berta D; Bindi S; Cameron A; Cappella P; Carpinelli P; Catana C; Forte B; Giordano P; Giorgini ML; Mantegani S; Marsiglio A; Meroni M; Moll J; Pittalà V; Roletto F; Severino D; Soncini C; Storici P; Tonani R; Varasi M; Vulpetti A; Vianello P
    J Med Chem; 2005 Apr; 48(8):3080-4. PubMed ID: 15828847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3,4-Propylenedioxypyrrole-based conjugated oligomers via Pd-mediated decarboxylative cross coupling.
    Arroyave FA; Reynolds JR
    Org Lett; 2010 Mar; 12(6):1328-31. PubMed ID: 20192208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of estrogen receptor ligands with bridged oxabicyclic cores containing a diarylethylene motif: estrogen antagonists of unusual structure.
    Zhou HB; Comninos JS; Stossi F; Katzenellenbogen BS; Katzenellenbogen JA
    J Med Chem; 2005 Nov; 48(23):7261-74. PubMed ID: 16279785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total synthesis of epohelmin B and its analogues.
    Fürstner A; Korte A
    Chem Asian J; 2008 Feb; 3(2):310-8. PubMed ID: 18061922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of activity, selectivity, and liability profiles in 5-oxopyrrolopyridine DPP4 inhibitors leading to clinical candidate (Sa)-2-(3-(aminomethyl)-4-(2,4-dichlorophenyl)-2-methyl-5-oxo-5H-pyrrolo[3,4-b]pyridin-6(7H)-yl)-N,N-dimethylacetamide (BMS-767778).
    Devasthale P; Wang Y; Wang W; Fevig J; Feng J; Wang A; Harrity T; Egan D; Morgan N; Cap M; Fura A; Klei HE; Kish K; Weigelt C; Sun L; Levesque P; Moulin F; Li YX; Zahler R; Kirby MS; Hamann LG
    J Med Chem; 2013 Sep; 56(18):7343-57. PubMed ID: 23964740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereoselective synthesis of a dioxa-bicyclo[3.2.1]octane SGLT2 inhibitor.
    Mascitti V; Préville C
    Org Lett; 2010 Jul; 12(13):2940-3. PubMed ID: 20527898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of potential dual NK(1)/NK(3) receptor antagonists.
    Hanessian S; Babonneau V; Boyer N; Mannoury la Cour C; Millan MJ; De Nanteuil G
    Bioorg Med Chem Lett; 2014 Jan; 24(2):510-4. PubMed ID: 24374277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regioselective halogenations and subsequent Suzuki-Miyaura coupling onto bicyclic 2-pyridones.
    Bengtsson C; Almqvist F
    J Org Chem; 2010 Feb; 75(3):972-5. PubMed ID: 20025251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.